Development and validation of a simple and rapid Hplc method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study

Journal of Chromatographic Science

Volumn 46, Issue 9, 2008, Pages 809-812

  Souri, Effat ^a   Jalalizadeh, Hassan ^a   Saremi, Shahrooz ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56449120830     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/46.9.809     Document Type: Article

References (11)

1. J. Chilcott, P. Tappenden, M.L. Jones, and J.P. Wight. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther. 23: 1792-1823 (2001).
2. J. Waugh, G.M. keating, G.L. Plosker, S. Easthope, and D.M. Robinson. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 66: 85-109 (2006).
3. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer. An antidibetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270: 12953-56 (1995).
4. T.M. Willson, J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, S.R. Prakash, K.D. Beck, L.B. Moore, S.A. Kliewer, and J.M. Lehmann. The structure- activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39: 665-68 (1996).
5. D.A. Eckland and M. Danhof. Clinical pharmacokinetics of pioglitazaone. Exp. Clin. Endocrinol. Diabetes 108: 234-42 (2000).
6. W.Z. Zhong and M.G. Willams. Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction. J. Pharm. Biomed. Anal. 14: 465-73 (1996).
7. K. Yamashita, H. Murakami, T. Okuda, and M. Motohashi. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J. Chromatogr. B 677: 141-46 (1996).
8. P. Sripalakit, P. Neamhom, and A. Saraphanchotiwitthaya. High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J. Chromatogr. B 843: 164-69 (2006).
9. Y.J. Xue, K.C. Turner, J.B. Meeker, J. Pursley, M. Arnold, and S. Unger. Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study. J. Chromatogr. B 795: 215-26 (2003).
10. Z.J. Lin, W. Ji, D. Desai-Krieger, and L. Shum. Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 33: 101-108 (2003).
11. H. Wong, Y. Ozalp, A. Lainesse, and R.S. Alpan. In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. Arzneimittelforschung. 54: 618-24. (2004).